» Articles » PMID: 19228380

Expression of Bmi-1 is a Prognostic Marker in Bladder Cancer

Overview
Journal BMC Cancer
Publisher Biomed Central
Specialty Oncology
Date 2009 Feb 21
PMID 19228380
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

Background: The molecular mechanisms of the development and progression of bladder cancer are poorly understood. The objective of this study was to analyze the expression of Bmi-1 protein and its clinical significance in human bladder cancer.

Methods: We examined the expression of Bmi-1 mRNA and Bmi-1 protein by RT-PCR and Western blot, respectively in 14 paired bladder cancers and the adjacent normal tissues. The expression of Bmi-1 protein in 137 specimens of bladder cancer and 30 specimens of adjacent normal bladder tissue was determined by immunohistochemistry. Statistical analyses were applied to test the relationship between expression of Bmi-1, and clinicopathologic features and prognosis.

Results: Expression of Bmi-1 mRNA and protein was higher in bladder cancers than in the adjacent normal tissues in 14 paired samples (P < 0.01). By immunohistochemical examination, five of 30 adjacent normal bladder specimens (16.7%) versus 75 of 137 bladder cancers (54.3%) showed Bmi-1 protein expression (P < 0.05). Bmi-1 protein expression was intense in 20.6%, 54.3%, and 78.8% of tumors of histopathological stages G1, G2, and G3, respectively (P < 0.05). Expression of Bmi-1 protein was greater in invasive bladder cancers than in superficial bladder cancers (81.5% versus 32.5%, P < 0.05). In invasive bladder cancers, the expression of Bmi-1 protein in progression-free cancers was similar to that of cancers that have progressed (80.0% versus 82.4%, P > 0.5). In superficial bladder cancers, the expression of Bmi-1 protein in recurrent cases was higher than in recurrence-free cases (62.5% versus 13.7%, P < 0.05). Bmi-1 expression was positively correlated with tumor classification and TNM stage (P < 0.05), but not with tumor number (P > 0.05). Five-year survival in the group with higher Bmi-1 expression was 50.8%, while it was 78.5% in the group with lower Bmi-1 expression (P < 0.05). Patients with higher Bmi-1 expression had shorter survival time, whereas patients with lower Bmi-1 expression had longer survival time (P < 0.05).

Conclusion: Expression of Bmi-1 was greater in bladder cancers than in the adjacent normal tissues. The examination of Bmi-1 protein expression is potentially valuable in prognostic evaluation of bladder cancer.

Citing Articles

Correlations between C-myc expression, BMI-1 expression, and vaginal microecology with HPV-DNA load in patients with different cervical lesions.

Zhou Y, Zhu J, Zhang H Am J Transl Res. 2024; 16(6):2544-2553.

PMID: 39006286 PMC: 11236621. DOI: 10.62347/GPLZ1377.


Role of O-GlcNAcylation on cancer stem cells: Connecting nutrient sensing to cell plasticity.

Le Minh G, Reginato M Adv Cancer Res. 2023; 157:195-228.

PMID: 36725109 PMC: 9895886. DOI: 10.1016/bs.acr.2022.06.002.


The Crucial Roles of Bmi-1 in Cancer: Implications in Pathogenesis, Metastasis, Drug Resistance, and Targeted Therapies.

Xu J, Li L, Shi P, Cui H, Yang L Int J Mol Sci. 2022; 23(15).

PMID: 35897796 PMC: 9367737. DOI: 10.3390/ijms23158231.


Bladder Cancer-related microRNAs With In Vivo Efficacy in Preclinical Models.

Weidle U, Birzele F Cancer Diagn Progn. 2022; 1(4):245-263.

PMID: 35403137 PMC: 8988954. DOI: 10.21873/cdp.10033.


BMI1 promotes osteosarcoma proliferation and metastasis by repressing the transcription of SIK1.

Wang Q, Wu Y, Lin M, Wang G, Liu J, Xie M Cancer Cell Int. 2022; 22(1):136.

PMID: 35346195 PMC: 8961961. DOI: 10.1186/s12935-022-02552-8.


References
1.
Mihara K, Chowdhury M, Nakaju N, Hidani S, Ihara A, Hyodo H . Bmi-1 is useful as a novel molecular marker for predicting progression of myelodysplastic syndrome and patient prognosis. Blood. 2005; 107(1):305-8. DOI: 10.1182/blood-2005-06-2393. View

2.
Greenlee R, Murray T, Thun M . Cancer statistics, 2001. CA Cancer J Clin. 2001; 51(1):15-36. DOI: 10.3322/canjclin.51.1.15. View

3.
Eissa S, Kassim S, El-Ahmady O . Detection of bladder tumours: role of cytology, morphology-based assays, biochemical and molecular markers. Curr Opin Obstet Gynecol. 2003; 15(5):395-403. DOI: 10.1097/00001703-200310000-00008. View

4.
van der Lugt N, Domen J, Linders K, van Roon M, Te Riele H, van der Valk M . Posterior transformation, neurological abnormalities, and severe hematopoietic defects in mice with a targeted deletion of the bmi-1 proto-oncogene. Genes Dev. 1994; 8(7):757-69. DOI: 10.1101/gad.8.7.757. View

5.
Knowles M . Molecular genetics of bladder cancer. Br J Urol. 1995; 75 Suppl 1:57-66. View